Fifteen previously treated patients with measurable metastatic colon carcinoma were entered into a phase II study of vindesine, 3 mg/m2/week IV. Fourteen patients were evaluable for response. No objective tumor response was observed; however, seven patients experienced stable disease lasting 9, 10, 13, 15, 16, 19, and 26 weeks. Neurologic toxicity was the most common nonhematologic side-effect noted, manifesting as abdominal pain, constipation, paralytic ileus, or paresthesias. Leukopenia was observed in 16% of the 104 weekly courses. Nine patients had a 50% increase of their platelet counts above their pretreatment platelet counts; six patients had a doubling of their pretreatment platelet counts. Mean platelet counts revealed a linear increase with successive treatments during the initial 8 weeks of therapy. Serial CEA determinations demonstrated a parallel relationship with clinical progression in six of seven patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Al-Sarraf MA, Baker L, Talley RW, Kithier K, Vaitkevicius V (1979) The value of serial carcinoembryonic antigen in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer 44:1222–1225
Ahn YS, Harrington WJ, Seelman RC, Eytel CS (1974) Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med 291:376–380
Bayssas M, Gouvenia J, de Vassal F, Misset JL, Schwarzenberg L, Ribaud P, Mussett M, Jasmin C, Hayat M, Mathé G (1980) Vindesine. A new vinca alkaloid. In Mathé G, Muggia FM (eds) Cancer Chemo- and Immunopharmacology, vol 1: Chemopharmacology. Springer, New York, pp 91–97
Bedikian AY, Valdivieso M, Bodey GP, Freireich EJ (1979) Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother Pharmacol 2:263–266
Bedikian AY, Valdivieso M, Maroun J, Gutterman JV, Hersh EM, Bodey GP (1980) Evaluation of vindesine and MER in colorectal cancer. Cancer 46:463–467
Bonomi PD, Chandra G, Rossof AH, Klaassen D (1980a) Mitomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma. Cancer Chemother Pharmacol 5:39–42
Bonomi P, Rossof AH, Raynor WJ Jr, Quadeer M (1980b) Prediction of survival duration in patients with metastatic measurable colorectal adenocarcinoma. Proc Am Assoc Cancer Res 21:161
Currie VE, Wong PP, Krakoff IH, Young CW (1978) Phase I trial of vindesine in patients with advanced cancer. Cancer Treat Rep 62:1333–1336
Dyke RW, Nelson RL, Brade WP (1979) Vindesine. A short review of preclinical data. Cancer Chemother Pharmacol 2:229–232
Gralla RJ, Tan CTC, Young CW (1979) Vindesine. A review of phase III trials. Cancer Chemother Pharmacol 2:271–274
Hande K, Gay J, Gober J, Greco FA (1980) Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion. Cancer Treat Rev 7 [Suppl]:25–30
Hill JM, Loeb E (1961) Treatment of leukemia, lymphoma, and other malignant neoplasms with vinblastine. Cancer Chemother Rep 15:41–61
Holland JF, Scharlau C, Gailaui S (1973) Vincristine treatment of advanced cancer. A cooperative study of 92 cases. Cancer Res 33:1258–1264
Jackson CW, Edwards CC (1977) Evidence that stimulation of megakaryocytopoiesis by low-dose vincristine results from an effect on platelets. Br J Haematol 36:97–105
Kemeny N, Braun D (1981) Advanced colorectal carcinoma: clinical and laboratory parameters as indicators of response and survival. Proc Am Soc Clin Oncol 22:336
Klener P, Donner L, Hyncica V, Safrankova D (1974) Possible mechanism of vinblastine-induced thrombocytosis. Scand J Haematol 12:179–184
Mathé G, Misset JL, DeVassal F (1978) Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin's disease. Absence of cross-resistance with vincristine. Cancer Treat Rep 62:805–809
Miller TP, Jones SE, Chester AB, Dorr RT (1980) Phase II trials of vindesine in breast cancer, lymphoma, and other tumors: Future directions. Cancer Treat Rev 7 [Suppl]:81–86
Natale RB, Gralla RJ, Wittes RE, Golbey RB, Young CW (1980) Vindesine chemotherapy in lung cancer. Cancer Treat Rev 7:59–63
Ohnuma T, Holland JF, Andrijcuk A (1978) Initial clinical and pharmacologic studies with vindesine. Proc Am Assoc Cancer Res 19:129
Retsas S, Newton KA, Westbury G (1978) Vinca alkaloids and platelets. N Engl J Med 299:310
Retsas S, Peat I, Ashford R, Coe M, Maher J, Drury A, Hauham IWF, Philips RH, Newton KA, Westbury G (1980) Updated results of vindesine as a single agent in the therapy of advanced malignant melanoma. cancer Treat Rev 7 [Suppl]:87–90
Shani A, O'Connell MJ, Moertel CG, Schutt AJ, Silver A, Go VLW (1978) Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 88:627–630
Smith IE, Hedley DW, Powers TJ, McElwain TJ (1978) Vindesine: A phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 62:1427–1433
Stambaugh JE (1980) Phase II trials of vindesine in advanced neoplastic disease. Cancer Treat Rev 7 [Suppl]:75–79
Valdivieso M (1980) Phase I and II studies of vindesine. Cancer Treat Rev 7 [Suppl]:31–37
Young CW (1980) Vindesine trials at Memorial Sloan-Kettering Cancer Center. Cancer Treat Rev 7 [Suppl]:53–57
About this article
Cite this article
Pazdur, R., Rossof, A.H., Chandra, G. et al. Vindesine: Phase II evaluation in colon cancer and description of its platelet stimulating activity. Cancer Chemother. Pharmacol. 9, 41–44 (1982). https://doi.org/10.1007/BF00296760
- Colon Cancer
- Platelet Count
- Stable Disease